ImmunityBio Newsroom

ImmunityBio Analyst Ratings

BenzingaNov 22 19:56

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

BenzingaNov 22 01:35

ImmunityBio Analyst Ratings

BenzingaNov 13 01:06

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

BenzingaNov 13 01:06

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Barron'sOct 24 21:50

EF Hutton Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $30

Futu NewsOct 23 20:35

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

BenzingaOct 23 19:12

ImmunityBio Price Target Cut to $4.75/Share From $6.00 by Piper Sandler

Dow JonesAug 20 00:39

ImmunityBio Analyst Ratings

BenzingaAug 20 00:30

Jefferies Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $8

Futu NewsAug 19 20:32

Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)

TipRanksAug 19 20:16

Piper Sandler Maintains ImmunityBio(IBRX.US) With Hold Rating, Cuts Target Price to $4.75

Futu NewsAug 19 19:32

Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)

TipRanksAug 19 19:01

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)

TipRanksMay 6 20:35

ImmunityBio Analyst Ratings

BenzingaApr 29 19:50

Piper Sandler: Maintaining the ImmunityBio (IBRX.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.

Zhitong FinanceApr 29 19:50

Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6

BenzingaApr 29 19:50

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Healthcare Services (HCSG) and ImmunityBio (IBRX)

TipRanksApr 29 19:12

Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)

TipRanksMar 25 18:50

ImmunityBio Analyst Ratings

BenzingaMar 25 18:40